Pfizer Inc. (NYSE:PFE) Shares Sold by Hunter Associates Investment Management LLC

Hunter Associates Investment Management LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 1.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,085 shares of the biopharmaceutical company’s stock after selling 2,536 shares during the period. Pfizer makes up approximately 2.7% of Hunter Associates Investment Management LLC’s holdings, making the stock its 9th biggest position. Hunter Associates Investment Management LLC’s holdings in Pfizer were worth $6,595,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Advocacy Wealth Management Services LLC boosted its stake in Pfizer by 48.2% in the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 258 shares in the last quarter. Winch Advisory Services LLC boosted its stake in Pfizer by 69.6% in the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 336 shares in the last quarter. Ruggie Capital Group bought a new position in Pfizer in the 4th quarter worth about $44,000. Contravisory Investment Management Inc. lifted its stake in Pfizer by 182.6% during the 4th quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 745 shares during the period. Finally, Vestor Capital LLC bought a new position in Pfizer during the 3rd quarter valued at about $53,000. Institutional investors own 71.83% of the company’s stock.

In other Pfizer news, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $850,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 30,000 shares of Pfizer stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total value of $1,320,000.00. Following the sale, the insider now owns 80,094 shares of the company’s stock, valued at $3,524,136. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.

Several equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Goldman Sachs Group assumed coverage on shares of Pfizer in a research note on Tuesday, May 28th. They set a “conviction-buy” rating on the stock. Credit Suisse Group restated a “buy” rating and set a $48.00 target price on shares of Pfizer in a research note on Monday, June 17th. Morgan Stanley assumed coverage on shares of Pfizer in a research note on Tuesday, June 4th. They issued an “overweight” rating and a $48.00 price objective on the stock. Finally, Barclays reiterated a “hold” rating and issued a $41.00 price objective on shares of Pfizer in a research note on Thursday, May 9th. Thirteen analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and an average price target of $46.22.

PFE traded up $0.45 during trading on Monday, reaching $43.77. 20,234,126 shares of the company traded hands, compared to its average volume of 23,956,598. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 12-month low of $36.00 and a 12-month high of $46.47. The business’s fifty day simple moving average is $42.48. The stock has a market capitalization of $243.36 billion, a P/E ratio of 14.59, a P/E/G ratio of 2.51 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. The business had revenue of $13.12 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The company’s revenue was up 1.6% on a year-over-year basis. During the same period last year, the firm posted $0.77 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.88 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a dividend of $0.36 per share. The ex-dividend date is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.29%. Pfizer’s dividend payout ratio is currently 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Should you buy a closed-end mutual fund?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.